Inflection Biosciences
Paul was Senior Clinical Pharmacology Scientist at AstraZeneca and led the clinical pharmacology program to NDA/MAA for AZD9291/osimertinib, which had been awarded ‘breakthrough therapy’ status by the FDA. Formerly Paul was a Principal Scientist within Pharmaceutical Development (AZ) leading both the global biopharmaceutics network and the Medicines Evaluation science community (USA, SE, UK). He is Director and co-founder of Seda Pharmaceutical Development Services, a company providing pharmaceutical development and clinical pharmacology services and consultancy to the Pharma Industry.
This person is not in any offices
Inflection Biosciences
Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer.